Regenerative Medicine Program, Sinclair Centre for Regenerative Medicine, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada.
Arch Dis Child Fetal Neonatal Ed. 2018 Nov;103(6):F583-F588. doi: 10.1136/archdischild-2017-314451. Epub 2018 Jul 4.
Despite progress made in neonatal intensive care, complications of extreme preterm birth still contribute as the main cause of death to children below 5 years of age. Stem cell-based therapies-mesenchymal stromal cells in particular-offer a new hope in preventing and/or restoring organ damage in extreme preterm infants. Early phase clinical trials, fueled by promising preclinical studies on lung and brain injury, have begun. While the enthusiasm in the neonatal community is palpable, much more needs to be learnt about cell-based therapies. Maintaining the balance between temptation and a cautious, evidence-based approach will be critical for cell therapies to fulfil their promise in substantially improving the outcome of extreme preterm infants.
尽管新生儿重症监护取得了进展，但极早产儿的并发症仍然是 5 岁以下儿童死亡的主要原因。基于干细胞的疗法，特别是间充质基质细胞，为预防和/或恢复极早产儿的器官损伤带来了新的希望。早期临床试验已经开始，这得益于对肺和脑损伤的有前景的临床前研究。虽然新生儿界的热情是显而易见的，但对于细胞疗法还有更多需要了解。在细胞疗法充分发挥其潜力，显著改善极早产儿的预后方面，保持在诱惑和谨慎的基于证据的方法之间的平衡至关重要。
